

**TERMINAL DISCLAIMER TO OBTAIN A PROVISIONAL DOUBLE PATENTING  
REJECTION OVER A PENDING "REFERENCE" APPLICATION**

Docket Number (Optional)  
415852001100

In re Application of: Michelle L. STYLES et al.

Application No.: 10/585,916

Filed: January 12, 2005 (Int'l)

For: SUBSTITUTED BENZIMIDAZOLE SELECTIVE KINASE INHIBITORS (as amended)

The owner\*, Cytosia Research PTY LTD, of 100  
percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of  
any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any  
patent granted on pending **reference** Application Number 10/581,412, filed on June 1, 2006,  
as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said **reference** application may  
be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The owner  
hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it  
and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on  
the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that  
would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said  
**reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal  
disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent: granted  
on the pending **reference** application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a  
court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims  
canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term  
as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency,  
etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on  
information and belief are believed to be true; and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United  
States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 29,959

/Kate H. Murashige/ October 9, 2009  
Signature Date

Kate H. Murashige  
Typed or printed name

(858) 720-5112  
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

**WARNING: Information on this form may become public. Credit card information should not  
be included on this form. Provide credit card information and authorization on PTO-2038.**

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.